What is iMig?
In the next week and a half, you will be hearing a lot about the iMig meeting. This may leave you with a few questions, first one of which probably being “what is iMig?”
The International Mesothelioma Interest Group (iMig) is an independent international group of scientists and clinicians working to understand, cure and prevent mesothelioma. The group was started in 1991 and has since then been the organizer of bi-annual meetings meant to facilitate the sharing and collaboration of researchers and doctors interested in the study of mesothelioma and its potential treatments.
The Mesothelioma Applied Research Foundation and iMig share a productive history. In fact, many Meso Foundation grant recipients and Foundation’s Science Advisory Board members are also members of iMig. For example, the current chair of iMig, Dr. Steven Mutsaers is also an esteemed member of the Meso Foundation’s Science Advisory Board. In 2006, the two organizations hosted a joint meeting in Chicago, IL, and if you’ve ever attended a Meso Foundation Symposium, you may have noticed that many of our speakers are also collaborators of iMig.
iMig 2012 Meeting in Boston, MA
This year, iMig is hosting its bi-annual meeting in Boston, MA, and the Meso Foundation will, once again, be represented. Our own nurse practitioner and executive director, Mary Hesdorffer, MS, APRN, will co-chair a session, while another session will be dedicated entirely to our grant recipients who will present the findings of their Meso Foundation-funded research.
While most iMig members are well-aware of the Foundation’s prestigious peer-reviewed research program and many of them have applied for funding, the Meso Foundation will also take this opportunity to further promote its research program in our effort to obtain the most promising project applications available to speed up treatment development and to ultimately find a cure for mesothelioma.
As the meeting begins on September 11, we will keep you posted on current developments and updates from Boston.
Follow us on Facebook and Twitter to get the latest:
Follow our updates on Facebook and Twitter: